Delcath Systems (NASDAQ:DCTH) Receives Buy Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Delcath Systems (NASDAQ:DCTH) in a report released on Friday, Marketbeat Ratings reports. HC Wainwright currently has a $22.00 price target on the stock.

Other analysts have also issued research reports about the company. Craig Hallum assumed coverage on Delcath Systems in a research note on Friday, June 28th. They issued a “buy” rating and a $18.00 price target on the stock. Stephens reaffirmed an “overweight” rating and issued a $25.00 price target on shares of Delcath Systems in a research note on Tuesday, August 6th. Finally, StockNews.com lowered Delcath Systems from a “hold” rating to a “sell” rating in a research note on Thursday, October 17th. One analyst has rated the stock with a sell rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $21.50.

Delcath Systems Trading Down 2.0 %

Shares of NASDAQ:DCTH opened at $11.05 on Friday. Delcath Systems has a 1-year low of $2.25 and a 1-year high of $11.74. The firm has a market capitalization of $307.04 million, a PE ratio of -4.17 and a beta of 0.78. The business’s 50 day moving average is $9.19 and its 200-day moving average is $7.79.

Delcath Systems (NASDAQ:DCTH) last announced its quarterly earnings results on Monday, August 5th. The company reported ($0.48) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.12). The company had revenue of $7.77 million during the quarter, compared to analyst estimates of $5.00 million. Delcath Systems had a negative net margin of 474.22% and a negative return on equity of 312.48%. During the same period in the prior year, the firm earned ($0.58) EPS. On average, sell-side analysts predict that Delcath Systems will post -1.67 EPS for the current year.

Hedge Funds Weigh In On Delcath Systems

Several institutional investors have recently bought and sold shares of DCTH. Vanguard Group Inc. raised its position in Delcath Systems by 31.0% in the 1st quarter. Vanguard Group Inc. now owns 683,686 shares of the company’s stock valued at $3,261,000 after purchasing an additional 161,678 shares during the last quarter. BVF Inc. IL raised its position in Delcath Systems by 23.1% in the 1st quarter. BVF Inc. IL now owns 1,202,067 shares of the company’s stock valued at $5,734,000 after purchasing an additional 225,918 shares during the last quarter. Levin Capital Strategies L.P. raised its position in Delcath Systems by 12.2% in the 1st quarter. Levin Capital Strategies L.P. now owns 54,969 shares of the company’s stock valued at $262,000 after purchasing an additional 5,969 shares during the last quarter. Rosalind Advisors Inc. raised its position in shares of Delcath Systems by 155.1% during the second quarter. Rosalind Advisors Inc. now owns 2,650,389 shares of the company’s stock worth $22,184,000 after acquiring an additional 1,611,561 shares during the last quarter. Finally, Legato Capital Management LLC bought a new stake in shares of Delcath Systems during the second quarter worth $966,000. Institutional investors own 61.12% of the company’s stock.

About Delcath Systems

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.